Folgen
Jason M Norman
Jason M Norman
Sr Director, Vedanta Biosciences
Bestätigte E-Mail-Adresse bei vedantabio.com - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Disease-specific alterations in the enteric virome in inflammatory bowel disease
JM Norman, SA Handley, MT Baldridge, L Droit, CY Liu, BC Keller, ...
Cell 160 (3), 447-460, 2015
12662015
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
T Tanoue, S Morita, DR Plichta, AN Skelly, W Suda, Y Sugiura, ...
Nature 565 (7741), 600-605, 2019
9122019
Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome
CL Monaco, DB Gootenberg, G Zhao, SA Handley, MS Ghebremichael, ...
Cell host & microbe 19 (3), 311-322, 2016
4172016
Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense
KG Lassen, P Kuballa, KL Conway, KK Patel, CE Becker, JM Peloquin, ...
Proceedings of the National Academy of Sciences 111 (21), 7741-7746, 2014
4052014
Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity
TJ Nice, MT Baldridge, BT McCune, JM Norman, HM Lazear, M Artyomov, ...
Science 347 (6219), 269-273, 2015
3752015
Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities
JM Norman, SA Handley, HW Virgin
Gastroenterology 146 (6), 1459-1469, 2014
2102014
The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells
JM Norman, M Mashiba, LA McNamara, A Onafuwa-Nuga, E Chiari-Fort, ...
Nature immunology 12 (10), 975-983, 2011
1132011
Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers
M Dsouza, R Menon, E Crossette, SK Bhattarai, J Schneider, YG Kim, ...
Cell Host & Microbe 30 (4), 583-598. e8, 2022
742022
Computer-guided design of optimal microbial consortia for immune system modulation
RR Stein, T Tanoue, RL Szabady, SK Bhattarai, B Olle, JM Norman, ...
Elife 7, e30916, 2018
742018
VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial
T Louie, Y Golan, S Khanna, D Bobilev, N Erpelding, C Fratazzi, M Carini, ...
Jama 329 (16), 1356-1366, 2023
682023
ADP ribosylation factor 1 activity is required to recruit AP-1 to the major histocompatibility complex class I (MHC-I) cytoplasmic tail and disrupt MHC-I trafficking in HIV-1 …
ER Wonderlich, JA Leonard, DA Kulpa, KE Leopold, JM Norman, ...
Journal of virology 85 (23), 12216-12226, 2011
352011
Identification of trypsin-degrading commensals in the large intestine
Y Li, E Watanabe, Y Kawashima, DR Plichta, Z Wang, M Ujike, QY Ang, ...
Nature 609 (7927), 582-589, 2022
332022
Treatment of clostridium difficile infection
J Schneider, Y Kim, B Olle, S Reddy, J Norman, J Patarroyo
US Patent 9,999,641, 2018
292018
Fecal microbiota transplantation influences procarcinogenic Escherichia coli in recipient recurrent Clostridioides difficile patients
S Nooij, QR Ducarmon, JFJ Laros, RD Zwittink, JM Norman, WK Smits, ...
Gastroenterology 161 (4), 1218-1228. e5, 2021
252021
Increased diversity of gut microbiota during active oral immunotherapy in peanut allergic adults
Z He, VLG Vadali, RL Szabady, W Zhang, JM Norman, B Roberts, ...
Allergy 76 (3), 927, 2021
182021
1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut …
D Bobilev, S Bhattarai, R Menon, B Klein, S Reddy, B Olle, B Roberts, ...
Open Forum Infectious Diseases 6 (Supplement_2), S60-S60, 2019
162019
Treatment of Clostridium difficile infection
J Schneider, Y Kim, B Olle, S Reddy, J Norman, J Patarroyo
US Patent 10,064,904, 2018
122018
Treatment of clostridium difficile infection
J Schneider, Y Kim, B Olle, S Reddy, J Norman, J Patarroyo
US Patent 10,350,250, 2019
112019
Treatment of clostridium difficile infection
J Schneider, Y Kim, B Olle, S Reddy, J Norman, J Patarroyo
US Patent 10,456,431, 2019
102019
Randomized, double-blind, placebo (PBO)-controlled, single-and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of IBD: safety and …
J Silber, J Norman, T Kanno, E Crossette, R Szabady, R Menon, M Marko, ...
Inflammatory Bowel Diseases 28 (Supplement_1), S65-S66, 2022
72022
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20